Literature DB >> 10092066

Nuclear/cytoplasmic localization of the multiple endocrine neoplasia type 1 gene product, menin.

S C Huang1, Z Zhuang, R J Weil, S Pack, C Wang, H C Krutzsch, T A Pham, I A Lubensky.   

Abstract

Although the gene responsible for multiple endocrine neoplasia, type 1 (MEN1) has been identified recently, the function of its gene product, menin, is not known. To examine menin's biological role, we created an N-terminal tagged fusion protein to follow the distribution of menin in the cell. In all cell lines tested, menin was found both in the nucleus and the cytoplasm, but its localization was dependent on the phase of the cell cycle; during a nondividing phase, menin was found in the nucleus; during and immediately after cell division, it was found in the cytoplasm. To confirm the cellular localization seen with the N-terminal tagged protein, we developed and purified peptide-specific antibodies. One of these antibodies (NCI 624), which recognizes a domain (aa 383-395) of menin, was used in immunofluorescence studies to corroborate the N-terminal tagging results. Further confirmation of menin localization was obtained in a pituitary tumor cell line derived from a familial MEN1 patient, which contained a mixed cell population with either none, or one functional copy of the MEN1 gene. Our results indicate that menin functions principally as a nuclear protein but may be found in the cytoplasm during cell division.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092066

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  9 in total

1.  Menin immunoreactivity in secretory granules of human pancreatic islet cells.

Authors:  Larisa V Debelenko; Sunita Agarwal; Qiang Du; Wusheng Yan; Heidi S Erickson; Mones Abu-Asab; Mark A Raffeld; Steven K Libutti; Stephen J Marx; Michael R Emmert-Buck
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014 Nov-Dec

2.  A novel germline mutation of MEN 1 gene in a patient with acromegaly and multiple endocrine tumors.

Authors:  G Pinna; G Orgiana; C Carcassi; F Alba; F Cetani; E Pardi; C Marcocci; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

3.  Menin represses tumorigenesis via repressing cell proliferation.

Authors:  Ting Wu; Xianxin Hua
Journal:  Am J Cancer Res       Date:  2011-05-16       Impact factor: 6.166

4.  The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization.

Authors:  Yan Wang; Atsushi Ozawa; Shadia Zaman; Nijaguna B Prasad; Settara C Chandrasekharappa; Sunita K Agarwal; Stephen J Marx
Journal:  Cancer Res       Date:  2010-12-02       Impact factor: 12.701

Review 5.  The MEN1 gene and associated diseases: an update.

Authors:  T Tsukada; K Yamaguchi; T Kameya
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  MEN1 mutations and potentially MEN1-targeting miRNAs are responsible for menin deficiency in sporadic and MEN1 syndrome-associated primary hyperparathyroidism.

Authors:  Vince Kornél Grolmusz; Katalin Borka; Annamária Kövesdi; Kinga Németh; Katalin Balogh; Csaba Dékány; András Kiss; Anna Szentpéteri; Beatrix Sármán; Anikó Somogyi; Éva Csajbók; Zsuzsanna Valkusz; Miklós Tóth; Péter Igaz; Károly Rácz; Attila Patócs
Journal:  Virchows Arch       Date:  2017-06-08       Impact factor: 4.064

Review 7.  Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors.

Authors:  Anelia Horvath; Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

8.  Characterization of the MEN1 gene product, menin, by site-specific polyclonal antibodies.

Authors:  Y Ikeo; A Sakurai; K Hashizume
Journal:  Jpn J Cancer Res       Date:  1999-10

9.  Menin interacts with IQGAP1 to enhance intercellular adhesion of beta-cells.

Authors:  J Yan; Y Yang; H Zhang; C King; H-M Kan; Y Cai; C-X Yuan; G S Bloom; X Hua
Journal:  Oncogene       Date:  2008-12-15       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.